Cassava Investors Ink $31M Drug Suit Deal Alongside Appeal
Cassava Sciences investors have asked a Texas federal judge to preliminarily approve a $31 million settlement that ends their claims the pharmaceutical company inflated its stock prices with misleading information about...To view the full article, register now.
Already a subscriber? Click here to view full article